3.32
+0.30%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MiMedx Group
From its filings with the US Securities and Exchange Commission
MiMedx Group is based in Marietta, Georgia. Its shares trade on Nasdaq under the ticker MDXG. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $418.6m and net income of $48.6m. At that date it held total assets of $342.7m and shareholders' equity of $256.5m. By business, Wound brought in 66.0% of revenue, followed by Surgical at 34.0%.
MIMEDX is a pioneer and leader focused on helping humans heal. With nearly two decades of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life.
Since its inception, MIMEDX has focused on leading the industry with its deep expertise, unmatched peer-reviewed scientific and clinical data, robust intellectual property portfolio and an expansive library of real-world evidence supporting the use of our products. Historically, our sole focus has been on placental biologics. However, in 2024, we broadened our portfolio and began offering animal-derived products, or xenografts, and in 2025 and early 2026, we entered into agreements with manufacturers of other wound care modalities to further expand our product offering to serve our large and growing customer base. We continue to look for ways to broaden our portfolio, both inorganically and through our internal research and development efforts.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Aug 2007
- Employees
- 808
- Website
- mimedx.com ↗
- Head office
- 1775 W OAK COMMONS COURT, NE, MARIETTA, GA, 30062
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. M. Kathleen Behrens WilseyIndependent Chairman of the Board$301,874
- Mr. Joseph CapperChief Executive Officer, Director, since 2023$1.4m
- Mr. Douglas RiceChief Financial Officer$2.4m
- Ms. Ricci WhitlowExecutive Vice President, Chief Operating Officer$2.3m
- Mr. William HulseChief Administrative Officer, General Counsel$2.4m
- Ms. Kimberly Maersk-MollerChief Commercial Officer$4.0m
- Mr. James BiermanIndependent Director$234,374
- Mr. William HawkinsIndependent Director$225,874
- Dr. Cato LaurencinIndependent Director$232,499
- Mr. K. Todd NewtonIndependent Director, since 2019$235,874
- Ms. Tiffany OlsonIndependent Director$241,554
- Ms. Dorothy PuhyIndependent Director$242,388
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 94
- Environment
- 99
- Social
- 99
- Governance
- 83
- Women in the workforce
- 57%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MiMedx Group Inc has several key strengths that contribute to its success in the market. Firstly, the company demonstrates strong financial performance with consistent revenue growth and healthy profitability ratios. This allows MiMedx to invest in innovation and expand its product offerings. Furthermore, the company benefits from a robust research and development department, enabling it to develop high-quality medical products and stay ahead of competitors. MiMedx also enjoys a strong brand reputation and a loyal customer base due to its focus on delivering reliable and effective healthcare solutions.
Weaknesses
- Despite its strengths, MiMedx Group Inc faces certain weaknesses that could hinder its growth. Firstly, the company relies heavily on a few key customers, which poses a risk of significant revenue loss if any customer decides to switch suppliers. Additionally, the company has faced legal issues and regulatory scrutiny in the past, which have created negative publicity and damaged its reputation. Lastly, MiMedx operates in a highly competitive industry, facing intense competition from both established players and new entrants, which can impact its market share.
Opportunities
- MiMedx Group Inc has several opportunities to capitalize on in the market. Firstly, the increasing global demand for regenerative medicine and tissue-engineered products presents a significant growth opportunity for the company. MiMedx can leverage its expertise and expand its product portfolio to tap into this growing market. Additionally, partnerships and collaborations with healthcare providers and research institutions can help MiMedx gain access to new markets and increase its customer base. Furthermore, technological advancements in the healthcare industry provide opportunities for MiMedx to develop innovative solutions and gain a competitive edge.
Threats
- MiMedx Group Inc faces certain threats that could potentially impede its growth and profitability. Firstly, changes in healthcare policies and regulations can affect the reimbursement rates for medical products, impacting MiMedx's revenue. Additionally, the company operates in a highly regulated industry, and any non-compliance could lead to legal penalties and damage its reputation. Moreover, the possibility of new entrants and technological disruptions poses a threat to MiMedx's market position. Lastly, the company is exposed to fluctuations in raw material prices, which can impact its manufacturing costs and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.